Primary progressive multiple sclerosis or PPMS is characterized by a gradual worsening of neurological function from the beginning of the disease, rather than distinct relapses and recoveries. Ocrevus, also known by its generic name ocrelizumab, is approved for treating PPMS in adults. It works by targeting CD20 positive B cells, which are part of the immune system and can contribute to inflammation associated with multiple sclerosis.
Ocrevus is given by intravenous infusion. According to current U.S. prescribing information, the initial treatment consists of two 300 mg infusions given two weeks apart. After the initial doses, a 600 mg infusion is administered every six months. Patients are monitored during and after infusions because infusion related reactions can occur.
Before treatment begins, healthcare professionals generally review a person's medical history and perform specific assessments. These may include:
Vaccination planning is important because live or live attenuated vaccines are not recommended during treatment and after discontinuation until B cell recovery.
The purpose of treatment is to address disease activity and progression associated with PPMS. Individual responses can vary, so treatment decisions and follow up should be based on a person's medical history, symptoms, examination findings, and healthcare professional recommendations.
Because Ocrevus affects B cells, it can influence immune system function. Infections can occur, including serious infections, and treatment may need to be delayed when an active infection is present. Infusion reactions are another important consideration and may include symptoms such as itching, rash, breathing difficulties, or changes in blood pressure. Premedication is recommended before infusions to reduce the frequency and severity of these reactions.
Other safety considerations include:
The prescribing information also identifies reductions in immunoglobulins, malignancies, immune mediated colitis, liver injury, and progressive multifocal leukoencephalopathy as important warnings or precautions.
Ocrevus treatment for PPMS should therefore be considered as part of an individualized medical care plan. Healthcare professionals can evaluate whether treatment is appropriate and determine the necessary monitoring based on the patient's circumstances.
Ocrevus provides an established treatment option for adults with primary progressive multiple sclerosis. Understanding how the medicine is administered, why screening is performed, and which safety issues require monitoring can help patients have informed discussions with their healthcare professionals. This information is educational only and is not intended as medical advice, diagnosis, or a substitute for professional care.